Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)
Authors
Thomas Cluzeau•Marie Sébert•Pierre Fenaux
Journal
Journal of Clinical Oncology
Published
February 18, 2021
Sign in to comment
Add a comment...
Supporters
Support the authors with ResearchCoin
Topics
DOI
License
cc-by-nc-nd
No comments yet. Start the conversation!
Your contribution could help open science.